In last trading session, Verve Therapeutics Inc (NASDAQ:VERV) saw 1.04 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price level of $7.83 trading at -$0.24 or -2.97% at ring of the bell on the day assigns it a market valuation of $662.92M. That closing price of VERV’s stock is at a discount of -147.0% from its 52-week high price of $19.34 and is indicating a premium of 45.08% from its 52-week low price of $4.30.
For Verve Therapeutics Inc (VERV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Upright in the red during last session for losing -2.97%, in the last five days VERV remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $7.83 price level, adding 15.9% to its value on the day. Verve Therapeutics Inc’s shares saw a change of 38.83% in year-to-date performance and have moved -2.61% in past 5-day. Verve Therapeutics Inc (NASDAQ:VERV) showed a performance of 19.18% in past 30-days.
Wall Street analysts have assigned a consensus price target of 14 to the stock, which implies a rise of 44.07% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -78.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.8% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -67.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 22.10% while estimates for its earnings growth in next 5 years are of 2.28%.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
ALPHABET INC. is the top institutional holder at VERV for having 12.35 million shares of worth $60.26 million. And as of 2024-06-30, it was holding 14.6618 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 6.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9632 of outstanding shares, having a total worth of $32.31 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 2.3 shares of worth $18.03 million or 2.72% of the total outstanding shares. The later fund manager was in possession of 2.15 shares on Sep 30, 2024 , making its stake of worth around $16.87 million in the company or a holder of 2.54% of company’s stock.
